General Electric (NYSE:GE) has finalized the sale of its BioPharma unit to Danaher (NYSE:DHR), giving its $20B, after accounting for taxes, fees and factored receivable balances.
The anticipated proceeds have been central to CEO
Larry Culp’s efforts to chip away at GE’s debilitating debt load and
help it recover from a deep slump in recent years.
The companies won approval from the Federal Trade Commission earlier this month for the deal, which was announced in early 2019.
https://seekingalpha.com/news/3557071-ge-finally-closes-20b-biopharma-sale
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.